# OPIANT PHARMACEUTICALS, INC.

OPIANT PHARMACEUTICALS, INC. is a company headquartered in Santa Monica, CA, United States.

## Company overview

- **Legal name:** OPIANT PHARMACEUTICALS, INC.
- **Former names in filing history:** Lightlake Therapeutics Inc. (2009-09-28 to 2016-01-22); Madrona Ventures, Inc. (2007-01-11 to 2009-10-09)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Santa Monica, CA, United States
- **Fiscal year end:** December 31
- **SEC CIK:** 0001385508

## About

OPIANT PHARMACEUTICALS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001385508, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-15, it reported annual revenue of USD 47,785,478; net income of USD 3,008,790; total assets of USD 70,427,798 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $47.8M (USD 47,785,478)
- **Net income:** $3.0M (USD 3,008,790)
- **Total assets:** $70.4M (USD 70,427,798)
- **Cash and equivalents:** $37.9M (USD 37,853,947)
- **Operating cash flow:** $1.9M (USD 1,926,489)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $29.6M (USD 29,625,181)
- **Net income:** -$1.9M (USD -1,861,449)
- **Total assets:** $60.6M (USD 60,613,032)
- **Cash and equivalents:** $48.3M (USD 48,251,336)
- **Operating cash flow:** -$2.0M (USD -2,028,773)
- **Later filings:** Revenue: shown as originally filed; later filings report different values for the same periods.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $40.5M (USD 40,519,800)
- **Net income:** $11.6M (USD 11,593,050)
- **Total assets:** $40.3M (USD 40,280,509)
- **Cash and equivalents:** $31.0M (USD 30,980,473)
- **Operating cash flow:** $4.1M (USD 4,063,890)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $14.0M (USD 13,982,177)
- **Net income:** -$21.2M (USD -21,195,316)
- **Total assets:** $29.4M (USD 29,386,324)
- **Cash and equivalents:** $24.6M (USD 24,613,638)
- **Operating cash flow:** -$522,972 (USD -522,972)
- **Later filings:** Total assets, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2023-03-02 — period 2023-03-02 — 8-K
- Form 8-K — filed 2023-03-01 — period 2023-03-01 — 8-K
- Form 8-K — filed 2023-02-27 — period 2023-02-23 — 8-K
- Form 8-K — filed 2023-02-07 — period 2023-02-02 — 8-K
- Form 8-K — filed 2023-01-09 — period 2023-01-04 — 8-K
- Form SC 13G — filed 2022-11-28 — SC 13G
- Form 8-K — filed 2022-11-15 — period 2022-11-13 — 8-K
- Form 10-Q — filed 2022-11-14 — period 2022-09-30 — 10-Q
- Form 8-K — filed 2022-11-14 — period 2022-11-13 — 8-K
- Form 10-Q — filed 2022-08-11 — period 2022-06-30 — 10-Q
- Form 8-K — filed 2022-08-11 — period 2022-08-11 — 8-K
- Form 8-K — filed 2022-06-14 — period 2022-06-14 — 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/opiant-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology